MyCural Therapeutics develops drug candidates for cancer treatment. The objective is to develop new treatments for patients with aggressive, resistant, metastatic high-risk tumors.
The investment is being made in conjunction with UU Invest.
“Being able to collaborate with our colleagues in Uppsala, who have extensive experience in life science, is a great advantage for us,” says Jonas Nilsson, Investment Manager, LiU Invest.
In connection with this investment, private investors are also participating, and the company is raising approximately SEK 3 million in total.
